Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis

被引:17
|
作者
Hazan, Jemma [1 ]
Wing, Michelle [1 ]
Liu, Kathy Y. [1 ]
Reeves, Suzanne [1 ]
Howard, Robert [1 ]
机构
[1] UCL, Div Psychiat, London, England
来源
关键词
DEMENTIA; ALZHEIMER'S DISEASE; CSF; ALZHEIMERS-DISEASE; CSF BIOMARKERS; DIAGNOSTIC IMPACT; PHOSPHORYLATED TAU; COST-EFFECTIVENESS; DEMENTIA; AMYLOID-BETA(1-42); PERFORMANCE; FRAMEWORK;
D O I
10.1136/jnnp-2022-329530
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The analytical and clinical validity of cerebrospinal (CSF) biomarkers has been extensively researched in dementia. Further work is needed to assess the ability of these biomarkers to improve diagnosis, management and health outcomes in the clinical setting Objectives To assess the added value and clinical utility of CSF biomarkers in the diagnostic assessment of cognitively impaired patients under evaluation for Alzheimer's disease (AD). Methods Systematic literature searches of Medline, EMBASE, PsycINFO and Web of Science research databases were conducted on 17 December 2022. Data from relevant studies were extracted and independently screened for quality using a tool for bias. Clinical utility was measured by clinicians' changes in diagnosis, diagnostic confidence and patient management (when available), after their examination of patients' CSF biomarkers. Cost-effectiveness was assessed by consideration of additional cost per patient and quality-adjusted life years. Results Searches identified 17 studies comprising 2090 patient participants and 593 clinicians. The meta-analysis revealed that clinicians' use of CSF biomarkers resulted in a pooled percentage change in diagnosis of 25% (95% CI 14 to 37), an increase in diagnostic confidence of 14% (95% CI 9 to 18) and a pooled proportion of patients whose management changed of 31% (95% CI 12 to 50). CSF biomarkers were deemed cost-effective, particularly in memory services, where pre-test AD prevalence is higher compared with a primary care setting. Conclusions CSF biomarkers can be a helpful additional diagnostic tool for clinicians assessing patients with cognitive impairment. In particular, CSF biomarkers consistently improved clinicians' confidence in diagnosing AD and influenced on diagnostic change and patient management. Further research is needed to study the clinical utility of blood-based biomarkers in the clinical setting.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [21] Potential biomarkers for cerebral small vessel disease with cognitive impairment: a systematic review and meta-analysis
    Liao, Libin
    Huang, Weiquan
    Ma, Rongchao
    He, Xuan
    Su, Moxi
    Sha, Dujuan
    FRONTIERS IN AGING NEUROSCIENCE, 2025, 16
  • [22] The utility of the Montreal cognitive assessment (MoCA) in detecting cognitive impairment in surgical populations - A systematic review and meta-analysis
    Danquah, Mercy O.
    Yan, Ellene
    Lee, Jun Won
    Philip, Kaylyssa
    Saripella, Aparna
    Alhamdah, Yasmin
    He, David
    Englesakis, Marina
    Chung, Frances
    JOURNAL OF CLINICAL ANESTHESIA, 2024, 97
  • [23] Diagnostic Utility of Cerebrospinal Fluid α-Synuclein in Creutzfeldt-Jakob Disease: A Systematic Review and Meta-Analysis
    Kong, Yu
    Chen, Zhongyun
    Wang, Xue
    Wang, Wenjiao
    Zhang, Jing
    JOURNAL OF ALZHEIMERS DISEASE, 2022, 89 (02) : 493 - 503
  • [24] Kidney function and cognitive impairment: a systematic review and meta-analysis
    Pei, Xiaohua
    Bakerally, Nazia Begum
    Wang, Zhan
    Bo, Yun
    Ma, Yao
    Yong, Zhenzhu
    Zhu, Sizhu
    Gao, Fei
    Bei, Zhu
    Zhao, Weihong
    RENAL FAILURE, 2025, 47 (01)
  • [25] Biomarkers in the Cerebrospinal Fluid of Patients with Psychotic Disorders Compared to Healthy Controls: A Systematic Review and Meta-Analysis
    Romer, T.
    Jeppesen, R.
    Christensen, R.
    Benros, M.
    EUROPEAN PSYCHIATRY, 2022, 65 : S118 - S118
  • [26] Biomarkers in the cerebrospinal fluid of patients with psychotic disorders compared to healthy controls: a systematic review and meta-analysis
    Troels Boldt Rømer
    Rose Jeppesen
    Rune Haubo Bojesen Christensen
    Michael Eriksen Benros
    Molecular Psychiatry, 2023, 28 : 2277 - 2290
  • [27] Biomarkers in the cerebrospinal fluid of patients with psychotic disorders compared to healthy controls: a systematic review and meta-analysis
    Romer, Troels Boldt
    Jeppesen, Rose
    Christensen, Rune Haubo Bojesen
    Benros, Michael Eriksen
    MOLECULAR PSYCHIATRY, 2023, 28 (06) : 2277 - 2290
  • [28] Cognitive impairment and risks of osteoporosis: A systematic review and meta-analysis
    Zhao, Yangyang
    Chen, Heqing
    Qiu, Fei
    He, Jianquan
    Chen, Jian
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2023, 106
  • [29] Subclinical Hypothyroidism and Cognitive Impairment: Systematic Review and Meta-Analysis
    Pasqualetti, Giuseppe
    Pagano, Gennaro
    Rengo, Giuseppe
    Ferrara, Nicola
    Monzani, Fabio
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (11): : 4240 - 4248
  • [30] Antidepressants for cognitive impairment in schizophrenia - A systematic review and meta-analysis
    Vernon, Jeffrey A.
    Grudnikoff, Eugene
    Seidman, Andrew J.
    Frazier, Thomas W.
    Vemulapalli, Mani Sandhya
    Pareek, Priyanki
    Goldberg, Terry E.
    Kane, John M.
    Correll, Christoph U.
    SCHIZOPHRENIA RESEARCH, 2014, 159 (2-3) : 385 - 394